ADMA Biologics (ADMA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Company overview and product innovation

• Vertically integrated U.S.-based manufacturer specializing in intravenous immunoglobulin (IG) products derived from human plasma, with three FDA-approved products: ASCENIV, BIVIGAM, and Nabi-HB.

• Holds patents on donor identification, immunization schedules, and unique antibody composition, enabling differentiated products like ASCENIV.

• All operations, including plasma collection, manufacturing, and testing, are U.S.-based, with 10 internal plasma centers and new decade-long third-party supply contracts expanding access to over 250 centers.

• Manufacturing facility has a 600,000-liter annual capacity, with cycle times of 7–12 months per batch, providing strong forward visibility.

Market landscape and growth drivers

• U.S. IG market was $12 billion in 2023, expected to exceed $20 billion by 2030, with high per-capita usage and pricing.

• Company holds 2% unit share and 3.5–4% revenue share, benefiting from higher-margin products.

• Demand is driven by an aging population, improved diagnostics, and increased use of immunomodulatory drugs.

• ASCENIV targets complex Primary Immune Deficiency (PI) patients, addressing unmet needs with a unique antibody profile.

• Only 3% penetration of the 25,000-patient addressable market for ASCENIV, indicating significant growth potential.

Operational strategy and supply chain

• New third-party supply contracts will alleviate plasma bottlenecks, enabling onboarding of 250 centers by mid-2025.

• No plans to expand internal plasma centers beyond 10; focus is on leveraging third-party relationships.

• All donor screening and plasma pooling science is performed in-house, maintaining proprietary control.

• Manufacturing utilization is at 70–80%, with flexibility to shift production between BIVIGAM and ASCENIV as plasma availability increases.